Skip to main content
. Author manuscript; available in PMC: 2014 Jul 3.
Published in final edited form as: Bone Marrow Transplant. 2009 Aug 10;45(3):429–436. doi: 10.1038/bmt.2009.189

Figure 2.

Figure 2

OS in patients with AML/myelodysplastic syndrome (MDS) treated with fludarabine, melphalan and thiotepa and antithymocyte globulin regimen based on disease status at transplant. Overt relapse was associated with very poor outcomes.